Ang Li, MD, MS

Non-malignant hematologist. Epidemiology, health services, informatics researcher. #Thrombosis #Cancer #Microangiopathy. My views are my own

[Ang Li, MD, MS @AngLi_MD]

Our recent study demonstrates that the EHR-CAT risk model is externally valid and applicable across 184 health systems for prediction of cancer associated thrombosis.

doi:10.1001/jamanetworkopen.2025.44428

[Ang Li, MD, MS @AngLi_MD]

Tired of spending all day chart-reviewing to find acute venous #thrombosis (PE/DVT)?
Try our validated VTE-BERT, a fine-tuned #NLP #AI model that extracts #VTE outcomes from full clinical notes.
🔗 https://t.co/xcOocTwXrl
📄 https://t.co/zjnh6L4PVp
@JTHjournal @BCMDeptMedicine

[Ang Li, MD, MS @AngLi_MD]

Tired of spending all day chart-reviewing to find acute venous #thrombosis (PE/DVT)?
Try our validated VTE-BERT, a fine-tuned #NLP #AI model that extracts #VTE outcomes from full clinical notes.
🔗 https://t.co/xcOocTwXrl
📄 https://t.co/zjnh6L4PVp
@JTHjournal @BCMDeptMedicine

[JAMA @JAMA_current]

Immune thrombotic thrombocytopenic purpura (iTTP) is an immune-mediated disorder characterized by thrombocytopenia and microangiopathic hemolytic anemia.

Learn more in this Review. https://t.co/YQF7gIkUu8

[Ang Li, MD, MS @AngLi_MD]

How important is #CHIP for #VTE risk in older adults with high prevalence? Find out in our newest publication @JTHjournal using #ARIC cohort by @smsaadatagah @SSukumarMD @CBallantyneMD @MaryCushmanMD Statistically significant but clinically small effect! https://t.co/BaJe5tsCXD

[Ang Li, MD, MS @AngLi_MD]

Preventing arterial #thromboembolism (ATE) in high-risk cancer patients should focus on modifiable CV risk factors. Kim et al.'s study explores the link between cancer, CV risk factors, and ATE. @JTHjournal. https://t.co/sRZSk73ntu

[Ang Li, MD, MS @AngLi_MD]

Looking forward to #ASH24! Our lab is actively recruiting new post-doctoral fellows:
https://t.co/vE0pV4NkED

[Ang Li, MD, MS @AngLi_MD]

Here's to another year of successful #ASH24 Hematology, ASH Education Program publication! Honored to be the the Special Section Editor for the last 3 years. https://t.co/ZIeeNZIqox

[Marc Carrier @MarcCarrier1]

Dr. @AngLi_MD reported external validation of the EHR-CAT score (adaptions of the Khorana risk score) in 187 health care system (over 400,000 patients).

Let’s implement this in EPIC to stratify patients according to their underlying risk of VTE!
#ASH24

[Mark Jiang @markjyjiang]

ctDNA is an underexplored tool for the prognostication of cancer-associated VTE. The # of pathogenic ctDNA mutations is independently predictive of VTE risk. https://t.co/vQs9bw0D1g @JTHjournal @AngLi_MD @BCMHemeOnc

[Ang Li, MD, MS @AngLi_MD]

#ASH24 Dr. @saratain presented our prospective cohort study of 101 pediatric patients undergoing allogeneic transplant @TexasChildrens. We found an 17% incidence of thrombotic microangiopathy (TMA) at 1-year & distinct longitudinal changes in sC5b9, Ba, ANG-1 & ANG-2 biomarkers!

[Ang Li, MD, MS @AngLi_MD]

Congratulations to @smsaadatagah for presenting an oral abstract at #ASH24 annual meeting. He showed a mild association between #CHIP and #VTE in ARIC prospective cohort driven by TET2 @BCM_InternalMed @BCMDeptMedicine

[Ang Li, MD, MS @AngLi_MD]

Looking forward to #ASH24! Our lab is actively recruiting new post-doctoral fellows:
https://t.co/vE0pV4NkED

[Ang Li, MD, MS @AngLi_MD]

Baylor College of Medicine is seeking a full-time classical hematologist to join our clinical and research programs. We are located in the heart of Houston (not Waco): https://t.co/vvHJFjkri2

[Ang Li, MD, MS @AngLi_MD]

Racial disparity in cancer mortality persists at large in the U.S. but is mitigated in single-payer healthcare system like the VA. Under-captured SDoH such as access to care likely explains the discrepancy. https://t.co/o4CmJDb2Wu @nrfillmore

[Ang Li, MD, MS @AngLi_MD]

Similar survival outcomes can be achieved for aggressive large B-cell lymphoma in a safety-net hospital system with robust financial assistance program! R-IPI plus several other factors are prognostic @markjyjiang @ChrisRFlowersMD https://t.co/mIuLZeQBfY

[Ang Li, MD, MS @AngLi_MD]

Not all #lymphomas are created equal. Different histology types pose unique #thrombosis risks. New #VTE risk assessment model in #lymphoma patients across 3 patient cohorts: https://t.co/FOdTv0doXF @ShenglingMa

[Ang Li, MD, MS @AngLi_MD]

Should isolated splanchnic vein thrombosis be included in the outcome definition for "cancer associated thrombosis"? Our study shows that they are managed very differently. A multi-center study is needed! @MarcCarrier1 @KSanfilippoMD @rushadpatell
https://t.co/0mcooWxKgc

[JTH @JTHjournal]

Anticoagulation in #cancer-associated splanchnic vein #thrombosis (SpVT) requires judicious consideration for thrombotic & bleeding risk.

This study by Shang et al. delves deeper into the natural history & management of SpVT. @AngLi_MD
https://t.co/SMOYg7e4HC @ELShematology

[Ang Li, MD, MS @AngLi_MD]

The Hematology, ASH Education Program is now available online to complement the education sessions at #ASH2023. Read about the latest education and mini-review topics here! https://t.co/f69A6RBk6J